Ermium Therapeutics to present promising preclinical data highlighting the therapeutic potential of Ermium immunomodulators for the treatment of systemic lupus erythematosus at the annual ACR Convergence 2022 conference

CXCR4 as a novel target in immunology: moving away from typical antagonists

Dr Annegret Van der Aa (CSO – CDO), Dr Kristof Van Emelen (Head of Medicinal Chemistry) and Dr Jean-Philip Herbeuval (Scientific founder) are co-author of “CXCR4 as a novel target in immunology: moving away from typical antagonists” published online in Future Drug Discovery (vol 4, n°2) – see link. This publication is at the cornerstone of Ermium CXCR4-specific immunomodulators and their uses in auto-immune diseases. It gathers scientists from Université Paris Cité, CNRS, University of Glasgow, and Ermium Therapeutics.

Ermium Therapeutics extends its initial €6,3 M funding to €12,3 M

Formation of a Scientific Advisory Board

Ermium Therapeutics at the Biotech Showcase

Ermium Therapeutics is a presenting company at the Biotech Showcase, investor conference for innovators.

Ermium Therapeutics at BIO-Europe Fall 2021

Ermium Therapeutics is participating to BIO-Europe Fall 2021 meeting and its partnering sessions

Ermium Therapeutics achieves breakthrough R&D progress with its proprietary CXCR4-targeted functionally selective immunomodulator

Besides the already published in vitro and vivo proof of concept data, Ermium established, with a proprietary CXCR4-targeted non antagonist immunomodulator, proof of concept in three in vivo models, including in a well-known murine disease model of systemic lupus erythematosus.

Ermium Therapeutics at Bio€quity Europe

Ermium Therapeutics is a presenting company at Bio€quity Europe and is participating to the partnering meetings

Kristof Van Emelen, PhD, joins Ermium Therapeutics as Head of Medicinal Chemistry

Ermium Therapeutics is strengthening its management team with the appointment of Kristof Van Emelen as Head of Medicinal Chemistry.